KaloBios Pharmaceuticals Inc. (HGEN)
(Delayed Data from OTC)
$1.15 USD
-0.07 (-6.07%)
Updated May 3, 2019 01:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
HGEN 1.15 -0.07(-6.07%)
Will HGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HGEN
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
HGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates